Quick Answer
Celldex Therapeutics, Inc. reported Operating Income of -$287.37 million for fiscal year 2025.
Celldex Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$287.37M | -47.3% |
| 2024 | -$195.08M | -26.2% |
| 2023 | -$154.54M | -34.1% |
| 2022 | -$115.23M | -61.7% |
| 2021 | -$71.24M | -12.5% |
| 2020 | -$63.35M | -15.1% |
| 2019 | -$55.03M | +64.8% |
| 2018 | -$156.44M | -28.7% |
| 2017 | -$121.53M | +8.6% |
| 2016 | -$132.92M | -2.6% |
| 2015 | -$129.54M | -5.8% |
| 2014 | -$122.43M | -50.3% |
| 2013 | -$81.44M | -40.2% |
| 2012 | -$58.08M | -33.8% |
| 2011 | -$43.40M | -572.3% |
| 2010 | -$6.46M | +82.5% |
| 2009 | -$36.85M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$73.62M | -41.2% | -15.3% |
| June 30, 2025 | -$63.86M | -37.9% | -1.8% |
| March 31, 2025 | -$62.74M | -54.5% | -20.4% |
| September 30, 2024 | -$52.13M | -26.4% | -12.5% |
| June 30, 2024 | -$46.32M | -39.5% | -14.1% |
| March 31, 2024 | -$40.61M | -25.1% | +1.5% |
| September 30, 2023 | -$41.24M | -48.9% | -24.2% |
| June 30, 2023 | -$33.20M | +8.8% | -2.3% |
- Celldex Therapeutics, Inc. showed a decrease of -47.3% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Celldex Therapeutics, Inc.’s operating income has declined by 679.8% (from -$36.85 million to -$287.37 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: